A new Series D financing round worth $35 million will support Calithera Biosciences Inc.’s Phase I study of its cancer candidate, CB-839. The compound is designed to block cancer cell growth through inhibition of glutaminase. In preclinical studies, Calithera showed potent and selective activity of CB-839 against multiple tumor types.